Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy

Sarcoma or sarcomatoid malignancies are a set of mesenchymal-origin malignancies with vast heterogeneity in clinical and molecular characteristics. Anaplastic lymphoma kinase (ALK) is a tyrosine kinase oncoprotein expressed by several tumors, including sarcomas. Crizotinib is an effective ALK inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jinchun, Hu, Yongbin, Abdihamid, Omar, Huang, Gengwen, Xiao, Sheng, Li, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551604/
https://www.ncbi.nlm.nih.gov/pubmed/34722239
http://dx.doi.org/10.3389/fonc.2021.684865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8551604/
https://www.ncbi.nlm.nih.gov/pubmed/34722239
http://dx.doi.org/10.3389/fonc.2021.684865

Ejemplares similares